Adjuvant chemotherapy in resected non-small cell lung cancer |
| |
Authors: | Cangiano Rodolfo |
| |
Affiliation: | U.O.C. Oncologia Medica, Istituto di Medicina Interna e Geriatria, Università Cattolica del S. Cuore, Policlinico "A. Gemelli", Roma, Italy. rocang@libero.it |
| |
Abstract: | There is still a high mortality ratio in completely resected non-small cell lung cancer patients either due to local or, more often, to metastatic recurrence. The NSCLC Collaborative Group Meta-analysis demonstrated a not statistically significant advantage in patients treated with cisplatin-based regimens. Many subsequent trials were unable to demonstrate the real effectiveness of cisplatin-based adjuvant chemotherapy with a significant rate of toxicity. The IALT trial demonstrated little advantage in overall and disease-free survival with acceptable toxicity. A recent meta-analysis of trials including 5716 patients demonstrated the role of cisplatin-based chemotherapy as adjuvant treatment of resected non-small cell lung cancer even if results shoud be carefully examined. At present, adjuvant chemotherapy in non-small cell cancer should not be reserved to experimental trials. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|